Compare ResMed Inc. (RMD) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs iShares Silver Trust — how do they compare? ResMed Inc. trades at $228.86 (market cap $31.89B), while iShares Silver Trust trades at $54.84 (market cap $29.02B). The key difference: ResMed Inc. and iShares Silver Trust are close in size by market cap, and ResMed Inc. pays a 1.16% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and iShares Silver Trust for 89 Days on average.
| RMD | SLV | |
|---|---|---|
Market Cap | $31.89B | $29.02B |
Volume | 618,314 | 16,510,334 |
Sector | Health | — |
52-Week High | $277.88 | $105.57 |
52-Week Low | $182.82 | $42.40 |
Typical Hold Time | 51 Days | 89 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% with a bearish technical outlook. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Technical indicators show strong bearish momentum with 13 sell signals from moving averages, though RSI suggests potential oversold conditions. Recent news highlights silver's volatility amid Fed policy uncertainty and Treasury yield fluctuations.
Outlook remains cautious as silver faces pressure from rising rates and dollar strength. The ETF's structure provides pure silver exposure but carries metal price volatility risks. Near-term direction depends on Fed policy clarity and industrial demand trends, with technical support at $53-54 levels offering potential entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
